CTSO vs. ELMD, LAKE, NVRO, PROF, DRTS, INGN, BWAY, TLSI, CATX, and SKIN
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Electromed (ELMD), Lakeland Industries (LAKE), Nevro (NVRO), Profound Medical (PROF), Alpha Tau Medical (DRTS), Inogen (INGN), BrainsWay (BWAY), TriSalus Life Sciences (TLSI), Perspective Therapeutics (CATX), and Beauty Health (SKIN). These companies are all part of the "medical equipment" industry.
Cytosorbents vs.
Cytosorbents (NASDAQ:CTSO) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.
Cytosorbents presently has a consensus target price of $4.67, indicating a potential upside of 366.67%. Electromed has a consensus target price of $38.00, indicating a potential upside of 53.85%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Electromed.
Electromed has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Electromed has a net margin of 11.34% compared to Cytosorbents' net margin of -49.47%. Electromed's return on equity of 15.71% beat Cytosorbents' return on equity.
32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 6.6% of Cytosorbents shares are held by company insiders. Comparatively, 14.0% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Cytosorbents had 3 more articles in the media than Electromed. MarketBeat recorded 6 mentions for Cytosorbents and 3 mentions for Electromed. Electromed's average media sentiment score of 0.30 beat Cytosorbents' score of -0.11 indicating that Electromed is being referred to more favorably in the news media.
Cytosorbents received 420 more outperform votes than Electromed when rated by MarketBeat users. However, 90.91% of users gave Electromed an outperform vote while only 74.07% of users gave Cytosorbents an outperform vote.
Cytosorbents has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Electromed has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.
Summary
Electromed beats Cytosorbents on 13 of the 18 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
This page (NASDAQ:CTSO) was last updated on 3/11/2025 by MarketBeat.com Staff
Free CTSO Stock Alerts